This article is a correction to:
Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
Gianluca Mauri1,2,3†
Giorgio Patelli1,3†Viviana Gori1,3
Calogero Lauricella3
Benedetta Mussolin4
Alessio Amatu3Katia Bencardino3Federica Tosi3Erica Bonazzina3Emanuela Bonoldi3Alberto Bardelli4,5Salvatore Siena1,3
Andrea Sartore-Bianchi1,3*- 1Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy
- 2IFOM, Istituto Fondazione di Oncologia Molecolare ETS, Milan, Italy
- 3Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 4Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy
- 5Department of Oncology, Università degli Studi di Torino, Turin, Italy
A Corrigendum on
Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
by Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, Bencardino K, Tosi F, Bonazzina E, Bonoldi E, Bardelli A, Siena S and Sartore-Bianchi A (2022) Front. Oncol. 12:1030232. doi: 10.3389/fonc.2022.1030232
Incorrect Affiliation
In the published article, there was an error regarding the affiliations for Alberto Bardelli. Affiliation 2 should be removed from Alberto Bardelli. As well as having Affiliation 4, Alberto Bardelli should also have the following new affiliation Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.
There was also an error regarding the affiliation for Benedetta Mussolin. Affiliation 4 should be removed, and the new affiliation [Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy] should be added.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: MAP2K1, MEK, panitumumab, resistance mechanisms, colorectal cancer
Citation: Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, Bencardino K, Tosi F, Bonazzina E, Bonoldi E, Bardelli A, Siena S and Sartore-Bianchi A (2023) Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer. Front. Oncol. 13:1147497. doi: 10.3389/fonc.2023.1147497
Received: 18 January 2023; Accepted: 07 March 2023;
Published: 28 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Mauri, Patelli, Gori, Lauricella, Mussolin, Amatu, Bencardino, Tosi, Bonazzina, Bonoldi, Bardelli, Siena and Sartore-Bianchi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Andrea Sartore-Bianchi, YW5kcmVhLnNhcnRvcmViaWFuY2hpQHVuaW1pLml0
†These authors have contributed equally to this work and share first authorship